MotorK: Transaction in Own Shares

 

PMHH Publishes a Supplement to the Offer Document Regarding the Recommended Offer for Swedish Match and Reminds the Shareholders of the Terms of the Offer and of Certain U.S. Regulatory Requirements

 

GeNeuro’s ProTEct-MS Phase 2 Trial Data, Presented at the ECTRIMS 2022 Congress in Amsterdam, Confirms Synergistic Neuroprotective Potential of Temelimab in MS

 

Freedom Finance Europe Granted EuroCCP Membership

 

Valbiotis Will Present Significant Preclinical Results for Its Active Substance TOTUM•448 Against Fatty Liver Diseases (NAFL and NASH), at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)

 

ONWARD Schedules Webcast to Provide Third Quarter Business Update and Announces Participation at Upcoming Conferences

 

Pershing Square Holdings, Ltd. Announces Transactions in Own Shares and Weekly Summary of Transactions in Own Shares – 26 October 2022

 

New Analysis of UPLIZNA® (inebilizumab-cdon) Phase 3 Trial Data Demonstrates Importance of Reducing Plasmablasts to Help Prevent Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks

 

EMD Serono Showcases Depth of MS Portfolio at ECTRIMS Supporting Commitment to Advancing MS Care

 

Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022